Scholarlink

<p>This systematic review and meta-analysis evaluated the Friendship Bench (FB) intervention’s efficacy in relieving anxiety and depression among people living with HIV (PLHIV) and high-risk populations, explored intervention effect heterogeneity, and provided evidence for mental health-HIV care integration in resource-limited areas. Multiple databases were searched from inception to July 19, 2025; 6 RCTs (2203 participants) were included for meta-analysis via Stata 16.0. The pooled SMD was − 0.57 (95% CI: -1.41 to 0.28, <i>I</i>²=98.7%); PLHIV-only analyses (<i>n</i> = 5) showed no significant effect (SMD = 0.12, 95% CI: -0.03 to 0.27, <i>I</i>²=0.0%). Measurement tools and population type were key sources of heterogeneity, with the DASS-21 subgroup yielding consistently non-significant results. Current evidence is insufficient to confirm FB’s effectiveness, emphasizing the need for rigorous large-scale RCTs with standardized outcome measures.</p><p><i>Clinical trial registration</i>:&#xa0;This systematic review and metaanalysis has been prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: CRD420251063331; Registration date June 3, 2025).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of Friendship Bench in Alleviating Anxiety and Depression Symptoms Among People Living with HIV and High-Risk Populations: A Systematic Review and Meta-analysis

  • 期刊论文

  • 发表日期：

    2026年7月2日

查看全文
  • Jiao Li,
  • Jie Gao,
  • Chuying Chen,
  • Jiahong Ling,
  • Dan Cui,
  • Yanfen Fu

摘要

This systematic review and meta-analysis evaluated the Friendship Bench (FB) intervention’s efficacy in relieving anxiety and depression among people living with HIV (PLHIV) and high-risk populations, explored intervention effect heterogeneity, and provided evidence for mental health-HIV care integration in resource-limited areas. Multiple databases were searched from inception to July 19, 2025; 6 RCTs (2203 participants) were included for meta-analysis via Stata 16.0. The pooled SMD was − 0.57 (95% CI: -1.41 to 0.28, I²=98.7%); PLHIV-only analyses (n = 5) showed no significant effect (SMD = 0.12, 95% CI: -0.03 to 0.27, I²=0.0%). Measurement tools and population type were key sources of heterogeneity, with the DASS-21 subgroup yielding consistently non-significant results. Current evidence is insufficient to confirm FB’s effectiveness, emphasizing the need for rigorous large-scale RCTs with standardized outcome measures.

Clinical trial registration: This systematic review and metaanalysis has been prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: CRD420251063331; Registration date June 3, 2025).